Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash from Operations (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Cash from Operations for 6 consecutive years, with 12846000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 14.4% year-over-year to 12846000.0, compared with a TTM value of 37952000.0 through Sep 2025, up 34.41%, and an annual FY2024 reading of 56000000.0, down 22.32% over the prior year.
  • Cash from Operations was 12846000.0 for Q3 2025 at Ovid Therapeutics, down from 4754000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 160899083.0 in Q1 2021 and bottomed at 20086419.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 3489287.05, with a median of 11998504.0 recorded in 2021.
  • Peak annual rise in Cash from Operations hit 973.89% in 2021, while the deepest fall reached 639.88% in 2021.
  • Year by year, Cash from Operations stood at 11998504.0 in 2021, then increased by 23.53% to 9175732.0 in 2022, then fell by 29.81% to 11911000.0 in 2023, then rose by 15.61% to 10052000.0 in 2024, then fell by 27.8% to 12846000.0 in 2025.
  • Business Quant data shows Cash from Operations for OVID at 12846000.0 in Q3 2025, 4754000.0 in Q2 2025, and 10300000.0 in Q1 2025.